Insmed stock surges on Phase 3 trial win (NASDAQ:INSM)

Insmed stock surges over 120% as its oral candidate for bronchiectasis reaches Phase 3 trial goals. The company plans to file FDA application in Q4 2024. Read more here.

Related Keywords

Japan , ,Rolling Banknote ,Green Arrow ,Shadow Clipping Path ,New Jersey Based ,